Matthew J Ferrari1, Florence Fermon2, Fabienne Nackers3, Augusto Llosa3, Claire Magone3, Rebecca F Grais4. 1. Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA 16802 USA. 2. Epicentre, Paris, France. 3. Médecins Sans Frontières, Paris, France. 4. Médecins Sans Frontières, Paris, France Rebecca.grais@epicentre.msf.org.
Abstract
BACKGROUND: In 2009, a large meningitis A epidemic affected a broad region of northern Nigeria and southern Niger, resulting in more than 75 000 cases and 4000 deaths. In collaboration with state and federal agencies, Médecins Sans Frontières (MSF) intervened with a large-scale vaccination campaign using polysaccharide vaccine. Here the authors analyze the impact (cases averted) of the vaccination response as a function of the timing and coverage achieved. METHODS: Phenomenological epidemic models were fitted to replicate meningitis surveillance data from the Nigerian Ministry of Health/WHO surveillance system and from reinforced surveillance conducted by MSF in both vaccinated and unvaccinated areas using a dynamic, state-space framework to account for under-reporting of cases. RESULTS: The overall impact of the vaccination campaigns (reduction in meningitis cases) in Katsina State, northern Nigeria, ranged from 4% to 12%. At the local level, vaccination reduced cases by as much as 50% when campaigns were conducted early in the epidemic. CONCLUSIONS: Reactive vaccination with polysaccharide vaccine during meningitis outbreaks can significantly reduce the case burden when conducted early and comprehensively. Introduction of the conjugate MenAfriVac vaccine has reduced rates of disease caused by serogroup A Neisseria meningitidis in the region. Despite this, reactive campaigns with polysaccharide vaccine remain a necessary and important tool for meningitis outbreak response.
BACKGROUND: In 2009, a large meningitis A epidemic affected a broad region of northern Nigeria and southern Niger, resulting in more than 75 000 cases and 4000 deaths. In collaboration with state and federal agencies, Médecins Sans Frontières (MSF) intervened with a large-scale vaccination campaign using polysaccharide vaccine. Here the authors analyze the impact (cases averted) of the vaccination response as a function of the timing and coverage achieved. METHODS: Phenomenological epidemic models were fitted to replicate meningitis surveillance data from the Nigerian Ministry of Health/WHO surveillance system and from reinforced surveillance conducted by MSF in both vaccinated and unvaccinated areas using a dynamic, state-space framework to account for under-reporting of cases. RESULTS: The overall impact of the vaccination campaigns (reduction in meningitis cases) in Katsina State, northern Nigeria, ranged from 4% to 12%. At the local level, vaccination reduced cases by as much as 50% when campaigns were conducted early in the epidemic. CONCLUSIONS: Reactive vaccination with polysaccharide vaccine during meningitis outbreaks can significantly reduce the case burden when conducted early and comprehensively. Introduction of the conjugate MenAfriVac vaccine has reduced rates of disease caused by serogroup A Neisseria meningitidis in the region. Despite this, reactive campaigns with polysaccharide vaccine remain a necessary and important tool for meningitis outbreak response.
Authors: R F Grais; A J K Conlan; M J Ferrari; A Djibo; A Le Menach; O N Bjørnstad; B T Grenfell Journal: J R Soc Interface Date: 2008-01-06 Impact factor: 4.118
Authors: Matthew J Ferrari; Rebecca F Grais; Nita Bharti; Andrew J K Conlan; Ottar N Bjørnstad; Lara J Wolfson; Philippe J Guerin; Ali Djibo; Bryan T Grenfell Journal: Nature Date: 2008-02-07 Impact factor: 49.962
Authors: Matthew R Moore; Terri B Hyde; Thomas W Hennessy; Debra J Parks; Alisa L Reasonover; Marcella Harker-Jones; James Gove; Dana L Bruden; Karen Rudolph; Alan Parkinson; Jay C Butler; Anne Schuchat Journal: J Infect Dis Date: 2004-10-27 Impact factor: 5.226
Authors: Hélène Broutin; Solenne Philippon; Guillaume Constantin de Magny; Marie-Françoise Courel; Benjamin Sultan; Jean-François Guégan Journal: Int J Health Geogr Date: 2007-07-10 Impact factor: 3.918
Authors: Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anaïs Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen Journal: PLoS Med Date: 2018-01-24 Impact factor: 11.069
Authors: Matthew E Coldiron; Gabriel Alcoba; Iza Ciglenecki; Matt Hitchings; Ali Djibo; Anne-Laure Page; Celine Langendorf; Rebecca F Grais Journal: Trials Date: 2017-06-24 Impact factor: 2.279
Authors: Matthew E Coldiron; Bachir Assao; Anne-Laure Page; Matt D T Hitchings; Gabriel Alcoba; Iza Ciglenecki; Céline Langendorf; Christopher Mambula; Eric Adehossi; Fati Sidikou; Elhadji Ibrahim Tassiou; Victoire De Lastours; Rebecca F Grais Journal: PLoS Med Date: 2018-06-26 Impact factor: 11.069
Authors: Kurayi Mahachi; Joss Kessels; Kofi Boateng; Anne Eudes Jean Baptiste; Pamela Mitula; Ebru Ekeman; Laura Nic Lochlainn; Alexander Rosewell; Samir V Sodha; Bernadette Abela-Ridder; Albis Francesco Gabrielli Journal: Vaccine Date: 2022-08-13 Impact factor: 4.169